CEP-40783

• Description:

  CEP-40783 is a potent, selective and orally available inhibitor of AXL and c-Met with IC50 values of 7 nM and 12 nM, respectively.

• Product Name Alternative:

  RXDX-106

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  C-Met/HGFR; TAM Receptor

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/CEP-40783.html

• Purity:

  99.61

• Solubility:

  DMSO : 3.12 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=CN(C(C)C)C(N(C2=CC=C(F)C=C2)C1=O)=O)NC3=CC=C(OC4=CC=NC5=CC(OC)=C(OC)C=C45)C(F)=C3

• Molecular Formula:

  C31H26F2N4O6

• Molecular Weight:

  588.56

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Sheila M, et al. CEP-40783: A potent and selective AXL/c-Met inhibitor for use in breast, non-small cell lung (NSCLC), and pancreatic cancers. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA) : AACR; Mol Cancer Ther 2013;12 (11 Suppl) :Abstract nr C275.|[2]Jay F, et al. Antitumor activity of the dual AXL/c-Met inhibitor CEP-40783 in Champions primary TumorGraft? models of human non-small cell lung cancer (NSCLC) . [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA) : AACR; Mol Cancer Ther 2013;12 (11 Suppl) :Abstract nr C272.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• Isoform:

  Axl

• CAS Number:

  [1437321-24-8]